Andrea Lobo, PhD,  science writer—

Andrea Lobo holds a PhD in cell biology/neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She has authored multiple research papers in peer-reviewed journals.

Articles by Andrea Lobo

First SSc patient dosed in Phase 1 trial of CAR T-cell therapy

The first patient with systemic sclerosis (SSc) has been dosed in a Phase 1 trial of Adicet Bio’s investigational CAR T-cell therapy for autoimmune conditions, called ADI-001, the company has announced. Recruitment in the open-label trial (NCT06375993) is ongoing at one site in California. It’s expected…

SRF joins capital effort to advance drug development for scleroderma

The Scleroderma Research Foundation (SRF) announced that it has joined Vie Ventures to advance research and accelerate the development of innovative therapies for scleroderma and other autoimmune diseases. The venture capital firm unites biotech investors with autoimmune disease organizations to fund the translation of scientific discoveries into…

Ofev consistently slows lung function decline in SSc-ILD: Study

Lung function decline among people with systemic sclerosis-associated interstitial lung disease (SSc-ILD) was significantly slowed over the course of about four years of treatment with Ofev (nintedanib), according to a new analysis of trial data. The analysis was based on changes in forced vital capacity, or FVC, a measure…

Large study IDs risks for primary heart involvement in scleroderma

Wasting of the skeletal muscle, older age, being male, and having swollen joints are among the risk factors for primary heart involvement associated with systemic sclerosis (SSc), according to a study using a worldwide database. Particularly, intestinal symptoms, widened blood vessels underneath the skin, called telangiectasia, and older age…

Ofev effectiveness, safety seen over 3-year SENSCIS extension trial

Treatment with Ofev (nintedanib) for up to four years was associated with a sustained slowing of lung function decline in people with systemic sclerosis (SSc) associated with interstitial lung disease (SSc-ILD). That’s according to new results from the open-label study SENSCIS-ON (NCT03313180), a three-year extension of the…